Submitter Information



Similar documents
October 28, Cavex Holland Bv Mr. Richard Woortman Manager Technical Services Fustweg 5 Haarlem, 2031CJ The NETHERLANDS

February 5, Dear Kristin Pabst,

GE Healthcare MAR

February 22, Life Spine, Incorporated Mr. Randy Lewis General Manager 2401 West Hassell Road, Suite 1535 Hoffman Estates, Illinois 60169

May 7, Tactile Systems Technology Inc Daniel Chase V.P. Engineering & Operations 1331 Tyler St NE Minneapolis, Minnesota 55413

I~r it NOV SIE T AENCORE Tongue Suspension System OCE L_ August 3, (k) Summary. Appendix 3:

(k)Suminary k

Q(K SVJM~jPagelIof 3

510(k) Summary. Dentsply Implants. April 30, 2013

Phoenix Thera-Lase Systems, LLC Ms. Diane Rutherford Ken Block Consulting 1201 Richardson Drive, Suite 280 Richardson, Texas 75080

Section 5-510(k) Summary. This document is provided in the following pages. DEC

August 12, Oertli Instrumente AG Ms. Karin Rohr Head of Quality Management & Regulatory Affairs Hafnerwisenstrasse 4 CH 9442 Berneck Switzerland

January 12, Dear Amy Yang:

April 3, Dear Autumn Liu,

March 3, Dear Ms. Alice Gong,

Simpler Implant Solutions Inc Arbutus St. Vancouver, BC V6i 3Y9. haroldbergmanl~ogmail.com Telephone Fax K080115

November 20, Vascular Flow Technologies Ltd. Edwin Lindsay VP of QA/RA Prospect Business Centre, Gemini Cresent Dundee DD2 1TY United Kingdom

July 24, Dear Ms. Rhodes:

510(K) SUMMARY [as required by section (c)] FLIGHT 60 Ventilator 510(k) Number K IaO?2Z, JUL

510(K) SUMMARY. 510(k) Number KOS'00-r

Lewis Ward L.W. Ward and Associates, Inc Kirkwood Court Boulder, CO

May 5, Dear Mr. Courtney:

0 EC V-,) 133 Lj9a

August 21, TCM Associates Ltd Mr. Iain Alligan Technical Director 3 Hillgrove Business Park Nazeing Road Essex EN9 2HB United Kingdom

JUN 2 6 butt. EkoSonicTM Endovascular System with Rapid Pulse Modulation

University of Texas Medical School at Houston. April 14, 2015

510(k) SUMMARY MANI Needle and Suture Pack MANI, Inc.

SECTION 5 BARDEX TEMPERATURE-SENSING FOLEY CATHETER 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS INFORMATION

March 20, Dear Mr. Chen:

(k) SUMMARY DEC

2. Contact Person: Garo Mimaryan, MS., RAC 7 Technical Regulatory Affairs Specialist III 3. Phone Number: (914)

Brainreader ApS February 4, 2015 C/O Mette Munch QA Consultant Skagenvej 21 Egaa, 8250 DENMARK

DICOM Grid, Inc. January 25, Senior Consultant Biologics Consulting Group, Inc. 400 N. Washington Street, Suite 100 ALEXANDRIA VA 22314

Dental Morelli Ltda.

kok1 UQ 510(k)J Device {Applicant 510(k) Summary (per 21 CFR (c)) OCT Applicant

,11 DSA Cable, transducer and VS3, VS4 electrode, patient connector

September 17, Keeler Instruments Inc. Mr. Eugene R. Van Arsdale Marketing Manager 459 Parkway Broomall, PA 19008

Ad-tech Medical Instrument Corporation. Principal Consultant Quality & Regulatory Associates, LLC. 800 Levanger Lane. Stoughton, Wisconsin 53589

April 7, Acclarent, Inc. Mr. James Patrick Garvey II Sr. Manager, Regulatory Affairs 1525-B O'Brien Drive Menlo Park, CA 94025

June 9, Stryker Corporation Garry T. Hayeck, Ph.D. Senior Regulatory Affairs Specialist 2 Pearl Court Allendale, New Jersey 07401

EM GR.OUF DIPLOMAT. OT39?1 Company Name: (K)SUMMARY Oc. Submission Correspondent. Emergo Group, Inc. Company Address:

AW Server 510 (k) Summary of Safety and Effectiveness

Building 6, Suite 300 RyeBrook, NY C-ontact-N~ame: --- William H-. Schofield Director of TeleHealth Operations. Signal,_Radiofrequency

Ultimate Concepts Inc.

Ni Hau Industrial Co., Ltd. Ms. Lyn Chiu Sales Manager No. 15, Alley 125, Lane 318, Section 2, An Ho Road Tainan City, Taiwan 70967

SUMMARY OF SAFETY AND EFFECTIVENESS for Powered Muscle Stimulator

510(k) Summary. Atlanti STM Abutment and AtlantisTM Crown Abutment in Zirconia for Dentsply Ankylos Implant

sbchoi~kku.edu jeremy~sooil.com DANA Diabecare IlS Insulin Infusion pump Infusion pump Class II

MViAKIO. V.A hn2 ATTACHMENT I 610(K) SUMMARY. Submitter:

BMR ~131o-lvleccai Kesearcn Ltd.

L~l t l V~! MAY ?

FEB Mr. Gordon J. Peters Director Regulatory Compliance DocuSys, Incorporated 820 S. University Boulevard, Suite 3-H Mobile, Alabama 36609

510(k) Summary GlobalMedia Group, LIC. MAY CONiM

July 21, Dentca, Inc. c/o Mr. Claude Berthoin Denterprise International, Inc. 110 East Granada Blvd, Suite 207 Ormond Beach, Florida 32176

DEC The three components of the Axxent Electronic Brachytherapy System include the Controller, Balloon Applicators-BR and X-ray Source.

D I Z1. 510(k) Summary. Section 5. Siemens Medical Solutions USA, Inc. Oncology Care Systems. Date Prepared: September 09,

AgaMatrucx. NV2 21 Salem, NH oz (k) Sumnmary

TEXAS DEPARTMENT OF STATE HEALTH SERVICES. Executive Summary. Report on Regulation of Laser Hair Removal

510(k) Summary of Safety and Effectiveness JUN Hip prosthesis

November 17, Nanova Biomaterials, Inc. Mr. Andrew Ritts Senior Research Scientist 3806 Mojave Ct Columbia, Missouri, 65202

510(k) SUMMARY APR Date: 15 th December 2008

May 22, Rachel s Remedies, LLC Mrs. Rachel E. Jackson 2316 Delaware Ave. #174 Buffalo, New York 14216

September 25, Dear Ms. McCoy:

J UN (k) SUMMARY AS REQUIRED BY SECTION (C) Mrs. Mitsuko Yoneyama President. Submitted by:

Datrix, Inc NOV Appendix G. 510(k) Summary of Safety and Effectiveness for Datrix, Inc CardioServer ECG Management System

RAMSOFT BUG ,-. I"-, --I 2 N Tel: (416) Fax: (416) sales@ramsoftbiz (k) Summary

51O(K) SUMMARY: Therapy family of devices.

OCT 18 20U5Ibko. a. Submitter Name: Cosmetic Dental Materials Inc. (CDM Inc.) b. Submitter Address: 812 Water St. NE Albany OR 97321

Koqo8 go. ER35 ERO-SCAN Pro Hearing Test System. 61 Martin Lane Elk Grove Village, IL Manager of Instrumentation Products

MAY SECTION VIII. 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

510(k) Summary (c)

KIZ 2,33-3 p8 ~ 510(k) Summary. As required by 21 CFR (c) 510(k) Premarket Notification Submission AFrame Digital MobileCare Monitor.

October 29, Dear Ms. Hartnett:

foq8 510(k) Summary fo r PAIRIETEX ~ COMPOSITE Mesh

Performance. All You Need. All In One.

March 31, Etiometry, Inc. Richard Galgon Independent Consulting Associate Quintiles 5846 Cobblestone Lane Waunakee, Wisconsin 53597

Manufacturing Technology, Inc.

JN (k) Summary Device Identification: Device Description:

MAY Attachment (k) Summary 21 CER

MAR (k) SUMMARY OF SAFETY AND EFFECTIVENESS (21CFR ) 1. DATE PREPARED: 4/21/2008

Fresenius Medical Care

Dear Ms. Lucas: This letter corrects our substantially equivalent letter of February 18, 2016.

510(k) SUMMARY. OPTION-vyM Urinary Catheter

ELASTO-GEL MANIJKAH"O"NEY JUUjj 2. fudbthsarltvl of the wound fluid, while re~leas'ing

May 20, Ivoclar Vivadent Ag Ms. Donna Hartnett Director Regulatory Affairs Ivoclar Vivadent, Inc. 175 Pineview Drive Amherst, New York 14228

510(k) SUMMARY JUL Otoharmonics 0 Levo 9 System

W~c f-t. MAR 2 1 2fl09SC. 5 10(k) summary TRACTION MASTERS, INC. Traction Masters, Inc. AKA: Spinetronics, LLC 9737 NW 65 PL Parkland, Florida 33076

ItP. Section I. 510(k) Summary of Safety and Effectiveness. Applicant:

510(k) Summary SUBMITTER'S NAME, ADDRESS, TELEPHONE NUMBER, CONTACT PERSON, AND DATE SUMMARY PREPARED:

ATLANTIS Anterior Cervical Plate System ATLANTIS Translational Plate. 510(k) Summary. February 2007

510(K) Summary K102148

A division of Dermatology Associates of Atlanta PC. Laser Skin Care - Head to Toe. Our Services

DEC V,(9/azO (c 0 j

Section (K) Summary. Kimberly-Clark Corporation Winchester Road Neenah, WI 54956

Revision L Candela Proprietary Sheet 1 of 5 February 2005

IQ Corporation c/o Harold G. Haines, Ph.D. President SEP 1 f 2002 South Florida BioAssociates, Inc SW 127h Street Miami, Florida

Summary of Safety and Effectiveness

Histoacryl Flexible Topical Skin Adhesive April15, 2013

Food and Drug Administration 5 10(k) Notijfication - Partial & Total Ossicular Replacement Prostheses AUG I June 30, 2006

March 23, Vision Quest Industries, Inc. Mr. Mohammed Ouerghi Director of QA/RA 1390 Decision Street, Suite A Vista, CA 92081

Transcription:

S inddec 2 1 2011 510(k) Summary This 5 10(k) summary of safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act (SMDA) of 1990. The contents of the 5 1 0(k) summary have been provided in conformance with 21 CFR 807.92 Submitter Information SharpLight Technologies Ltd. 33 Lazarov St. Rishon Le Zion 75658, Israel Tel: (972) 3 9611969, Fax: (972) 3 9528890 Submission contact person: lian Sharon P.O.B. 4262, Zichron Yaacov 30900, Israel TEL: 972-52-8704904 Device Classification Proprietary Device Name: Common name: Product Code: Classification Name: Classification Regulation: 21 CFR 878.4810 Regulatory Class: 11 Dermatological Treatment Systems device family Multi-Application Dermatological Treatment device family Primary GEX, Secondary NUV, ONG, ONE, ONF Laser Surgical Instrument, for use in General and Plastic Surgery and Dermatology Identification of Legally Marketed Predicate Devices SharpLight - BEAMAX/FORMAX Pulse Light device family - K082876 Alma lasers - Harmony XLT Multi -Application Platform - K072564 Cutera Optional Pulsed Light Hand Piece Family - K050047 Palomar LuxiR Fractional Hand piece - K060069 Device Description The Dermatologic Treatment Systems (DTS) device family and optional hand pieces, including Intensive Pulse Light (IPL) Infrared light (IR) and Laser light technologies for dermatological treatments by delivery of energy to the human skin. The device family is a modification to the BeaMax! ForMax family (K(082876), pulsed light energy device based on a filtered, Xenon flashlamp. The DTS device family modification enhances capabilities of the legally cleared Beamax! Formax device family by adding new hand pieces that are now supporting Laser and IR technologies as well as the TPL technology. The Basic unit is a platform system, designed to support all treatment technologies hand pieces (i.e. IPL, [R and Laser). The embedded software is the heart of the control system which provides a control of all of the parameters to the relevant hand piece, where the operator has the access to modify some parameters via the touch screen and every hand piece has its own operating screen. Page I of 2

Intended Use of Device The DTS device family, a modification to the legally cleared device family (K082876), uses IPL, IR, Laser and RE energy sources, is intended for dermatological treatments. The DTS device family is indicated for dermatological treatments such as, but not limited to: " Hair removal in all skin types to the Fitzpatrick scale. Permanent Hair Reduction. * Treatment of Vascular Lesions " Treatment of Inflammatory Acne (acne vulgaris) " Treatment of Benign Pigmented Epidermal and Cutaneous Lesions including warts, scars and striae. " Treatment of Wrinkles, rhytids and Periorbital Wrinkles " Skin resurfacing (Acne scars) " Treatment of Tattoos " Treatment of Leg and Facial Vein Removal " Treatment of photocoagulation of soft tissue in dermatologic applications " Resurfacing of the skin, and for the treatment of facial wrinkles. Safety & Effectiveness The DTS device family was compared to the predicate devices in terms of intended use, indications for use, components, principles of operation, technological characteristics and safety features. Based on the performance results provided (including test results and clinical data) and the analysis of similarities and differences presented above, SharpLight Technologies Ltd. believes that the proposed device family safe & effectiveness is substantially equivalent to the predicate devices without raising new safety and/or effectiveness issues. Rational for Substantial Equivalency Similarities: The intended use and indications of the DTS device family are similar to the legally cleared predicate devices. The technology, performance and most of the specifications of the DTS device family are similar to the legally marketed predicate devices Differences: The DTS device family wider indications for use enhances their capability to perform dermatological treatments, by using the different technologies (IPL, Laser and IR), while predicate devices are capable of supporting partial treatments only. Substantial Equivalence Statement Based on the above, it is SharpLight's opinion that the proposed DTS device family is substantially equivalent in terms design principles, performance features and of safety & effectiveness to the unmodified BeaMax/ PorMax family (K082876) legally cleared device and to the legally cleared predicate devices referred to in chapter 4 of this submission. Page 2 of 2

DEPARTMENT OF HEALTH &HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -W066-G609 Silver Spring, MD 20993-0002 SharpLight Technologies, Ltd. % Mr. Ilan Sharon P.O. Box 4262 Zichron Yaacov Israel 30900 D EC 21 2011 Re: K1 11303 Trade/Device Name: Dermatological Treatment Device Family Regulation Number: 21 CFR 878.48 10 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class 11 Product Code: GEX, GEl Dated: December 16, 2011 Received: December 20, 2011 Dear Mr. Sharon: We have reviewed your Section 5 10(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your dev'ice is classified (see above) into either class 11 (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Regzister.

Page 2 - Mr. Ilan Sharon Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CER 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 80 1), please go to httu://www.fda.gov/aboutfda/centersoffices/cdrh/cdrhoffices/ucml 115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (2 1CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/medicaldevices/safetv/reportaproblem/default.htm for the CDRI-'s Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.pov/medical Devices/ResourcesforYou/Industry/default.htm. Sincerely yours, Enclosure Mark N. Mel gerson Director Division of Surgical, Orthopedic Office of Device Evaluation Center for Devices and Radiological Health

510(k) Number (if known): KI 111303 Device Name: Dermatological Treatment Systems Device Family : The Dermatological Treatment Systems device family and optional Hand Piece family are intended for use in aesthetic and cosmetic applications and in selective treatments required in the medical specialties of dermatology. The Dermatological Treatment device family and optional Hand pieces with 415-1200 nin wavelengths (with and without contact-cooling) are indicated for: * Hair removal and Permanent Hair Reduction in all skin types (I-VT) to the Fitzpatrick scale - Recommended wavelengths in the range of 635-950 nm, 730-950 nm or 580-950rn * Treatment of Pigmented and Vascular Lesions in all skin types (L-VI) to the Fitzpatrick scale - Recommended wavelength in the range of 535-950 n * Treatment of Inflammatory Acne (acne vulgaris) in skin types (I-V) to the Fitzpatrick scale - Recommended wavelength in the range of 415-950 nm * Treatment of Benign Pigmented Epidermal and Cutaneous Lesions including warts, scars and striae in all skin types (1-VT) to the Fitzpatrick scale - Recommended wavelength in the range of 580-950 nmn *Treatment of Benign Pigmented Epidermal, Cutaneous and Vascular Lesions including warts; scars and striae in skin types (I-V) to the Fitzpatrick scale - Recommended wavelength in the range of 535-680 nm & 860-l200nm Prescription Use X AN/R Over-The-Counter Use (Part 21 CFR 801 Subpart D) AN/R (21 CFR 801 Subpart C) Concurrence of CDRH, Office of Device Evaluation (ODE) q-yeb - 4 L (Division Sign-GM) 5l0(k)Number kni11)02pg Io

510(k) Number (if known): Ki 11303 Device Name: Dermatological Treatment device family : Continued from last page. The Dermatological Treatment device family and optional Infrared (IR) Hand Pieces with 850-1750 nm wavelengths (with contact cooling) is indicated for: *Dermnatologic Treatment such as, but not limited to: photocoagulation of soft tissue (Scars, Wrinkles, Rhytids and Periorbital Wrinkles) The Dermatological Treatment device family and optional Nd:YAG Laser 1064 nm Long Pulse (LP) Hand Pieces is indicated for: " Removal of unwanted hair, for stable long-term, or permanent, hair reduction through selective targeting of melanin in hair follicles. " Removal or lightening of unwanted hair (with and without adjuvant preparation) " Treatment of pseudofolliculitis barbae (PEB) Prescription Use X AN/R Over-The-Counter Use (Part 21 CFR 801 Subpart D) AN/R (21 CFR 801 Subpart C) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Oft) 510(kNtumm r )<Page 2 of 5

510(k) Number (if known): KI 111303 Device Name: Dermatological Treatment device family : Continued from last page. The Dermatological Treatment device family and optional Nd:YAG Laser 1064 unm Long Pulse (LP) and Q-Switched Hand Pieces is indicated for: " Benign vascular lesions such as. but not limited to treatment of:- Port wine stains; Hemangiomas; Warts, Superficial and deep telangiectasias (venulectasias); Reticular veins (0.1-4.0 mm dia.) of the leg; Rosacea; Venus lake; Leg veins; Spider veins; Poikiloderma of Civatte; Angiomas " Benign cutaneous lesions, such as. but not limited to: Wadts; Scars; Striae; Psoriasis " Benign pigmented lesions such as. but not limited to: Lentigos (age spots); Solar lentigos (sun spots); Cafe-au-lait macules; Seborrheic; keratoses; Nevi and nevus of Ota, Chlcasma; Verrucae; Skin tags; Keratoses; The removal of black, blue or green tattoos (significant reduction in the intensity of black and /or blue/black tattoos); Plaques " Pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment and for patients with lesions that have not responded to other laser treatments. " The non-ablative treatment of facial wrinkles, such as. but not limited to: Periocular wrinkles; Perioral wrinkles Prescription Use X AN/R Over-The-Counter Use (Part 21 CFR 801 Subpart D) AN/R (21 CFR 801 Subpart C) Concurrence of CDRH, Office of Device Evaluation (ODE) (Dvsion Sn-Off) I 5lO(k)Number Lii303 Page 3 of 5

51 0(k) Number (if known): KI 111303 Device Name: Dermatological Treatment device family : Continued from last page. Continued : The Dermatological Treatment device family and optional Nd:YAG Laser 1064 nm Long Pulse (LP) and Q-Switched Hand Pieces is indicated for: * Laser skin resurfacing procedures for the treatment of: Acne scars; Wrinkles * Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. * Indicated for use on all skin types (Fitzpatrick 1-VI), including tanned skin. The Dermatological Treatment device family and optional Nd:YAG Laser 532 nm Frequency Dabbler (FD) Long Pulse (LP) and Q-Switched Hand Pieces is indicated fo r: " Tattoo removal: Light blue; Yellow; Red; Green " Vascular lesions: Hemangiomas (Port wine stains/birthmarks, cavernous, cherry, spider); hemangiomas; Angiomas (cherry, spider); Telangiectasia; Spider nevi * Benign pigmented lesions, such as. but not limited to: Cafe-au-lait (macules); Lentigines (senile and solar); Freckles (ephelides); Chloasma; Nevi; Nevus spillus, Nevus of Ota; Becker's Nevi; " Other pigmented cutaneous lesions, such as. but not limited to: Verrucae; Skin tags; Keratoses; Plaques Prescription Use X AN/R Over-The-Counter Use (Part 21 CFR 801 Subpart D) AN/R (21 CER 801 Subpart C) Concurrence of CDRH, Office of Device Evaluation (ODE) (DivisiO Si 51o(k)Numnber-- LL1 Page 4 of 5

510(k) Number (if known): KI 111303 Device Name: Dermatological Treatment device family : Continued from last page. The Dermatological Treatment device family and optional Er:VAG Laser 2940 nm Long Pulse (LP) Hand Pieces, with standard and scanner accessory tips is indicated for: Use in soft tissue (skin, cutaneous tissue, subcutaneous tissue, striated and smooth tissue, muscle, cartilage meniscus, mucous membrane, lymph vessels and nodes; organs, and glands) such as, but not limited to: *Dermatology and plastic Surgery: Skin resurfacing3 Treatment of wrinkles; Epidermal nevi; Telangiectasia; Spider veins; Actinic chelitis; Keloids; Verrucae; Skin tags; Anal tags; Keratoses; Scar revision (including acne scars); Prescription Use X (Part 21 CFR 801 Subpart D) AN/OkOver-The-Counter AND/OR (21 CFR 801 Subpart Use C) Concurrence of CDRL-, Office of Device Evaluation (ODE) (Division Sign4JDff) I 510(k)Number K tha PageS5 of 5